logo
Plus   Neg
Share
Email

Halozyme Therapeutics Inc. (HALO) Climbed Sharply Following Upgrade

BMO Capital Markets upgraded its rating on shares of Halozyme Therapeutics Inc. (HALO) Monday to "Outperform" from "Market Perform."

Halozyme Therapeutics gapped up sharply Monday and climbed throughout the first 2 hours of trade. The stock finished up by 1.13 at $8.34 on above average volume and leaped to nearly a 4-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Follow RTT